Pharmacokinetics of the Hypoxia-Imaging Agent [123I]IAZA in Healthy Adults Following Exercise-Based Cardiac Stress

[1]  M. C. Feiters,et al.  Design of Radioiodinated Pharmaceuticals: Structural Features Affecting Metabolic Stability towards in Vivo Deiodination , 2017, European journal of organic chemistry.

[2]  T. DeGrado,et al.  Imaging of myocardial fatty acid oxidation. , 2016, Biochimica et biophysica acta.

[3]  I. Lawal,et al.  F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infection. , 2016, British medical bulletin.

[4]  Xiaomei Zhuang,et al.  PBPK modeling and simulation in drug research and development , 2016, Acta pharmaceutica Sinica. B.

[5]  Piyush Kumar,et al.  Bifunctional Metal - Nitroimidazole Complexes for Hypoxia Theranosis in Cancer , 2015 .

[6]  Piyush Kumar,et al.  The chemistry and radiochemistry of hypoxia-specific, radiohalogenated nitroaromatic imaging probes. , 2015, Seminars in nuclear medicine.

[7]  C. Reiners,et al.  Potassium iodide (KI) to block the thyroid from exposure to I-131: current questions and answers to be discussed , 2013, Radiation and environmental biophysics.

[8]  R. Gropler,et al.  Radionuclide Imaging of Myocardial Metabolism , 2010, Circulation. Cardiovascular imaging.

[9]  S. Husain.  Myocardial perfusion imaging protocols: is there an ideal protocol? , 2007, Journal of nuclear medicine technology.

[10]  A. McEwan,et al.  Scintigraphic imaging of focal hypoxic tissue: development and clinical applications of 123I-IAZA , 2002 .

[11]  S. McQuarrie,et al.  Dosimetry estimations for 123I-IAZA in healthy volunteers. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  A. McEwan,et al.  Identification of hypoxic regions in traumatic brain injury. , 1999, Clinical nuclear medicine.

[13]  A. McEwan,et al.  Clinical pharmacokinetics of 123I-IAZA in healthy volunteers. , 1999, Nuclear medicine communications.

[14]  L. Wiebe,et al.  A rapid and simple assay to determine the blood and urine concentrations of 1-(5-[123/125I]iodo-5-deoxyarabinofuranosyl)-2-nitroimidazole, a hypoxic cell marker. , 1998, Journal of pharmaceutical and biomedical analysis.

[15]  M. Parliament,et al.  Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside. , 1996, The British journal of cancer. Supplement.

[16]  M. Parliament,et al.  Imaging tumor hypoxia and tumor perfusion. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  L. Golberg,et al.  Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. , 1992, British Journal of Cancer.

[18]  J. D. Chapman,et al.  Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  S. Bergmann,et al.  Assessment of myocardial viability. , 2005, Seminars in nuclear medicine.